FEBRUARY 13, 2019ORLANDO, FL

Health 2.0 VentureConnect Pitch Competition

www.HIMSSConference.org #HITventure

Revolutionizes clinicians learning from patients • Patients can empower themselves to track their own progress• Healthcare providers gain a look at their function over time, in a way that

cannot be obtained during a typical clinical visitTimothy Vartanian, MD, PHD – Director of the Judith Jaffee Center at New York-Presbyterian Hospital / Weill Cornell Medical Center

Revolutionizes patient interaction with clinician• “You need to be empowered to live your life. I don’t want MS to weigh me

down. To me it something that I have, it doesn’t have me” – MS Patient Rebecca

• “It is nice to feel that someone is watching what is going on with you. So much of MS is what is going on in you head, and you need the objective evidencethat maybe things aren’t going as badly as you think they are” – MS Patient Regina

• Patients report improvement in their brain’s neuroplasticity

Problem: Multiple Sclerosis(MS) Patients do not have enough interaction with their clinical team to impact the course of their disease• Time consuming office based gold standard test (EDSS and MSFC) to

determine disease progression and physical impairment is:• Typically un-reimbursable • Scored differently by different clinicians

Solution: Engage MS Patients with combination of in person visits and telemedicine visits to improve outcomes and reduce costs• Predictive Artificial Intelligence (AI) Digital Therapeutics Mobile Platform

supplements existing MS “Gold Standard Tests” (EDSS and MSFC)• Can result in lower hospitalizations and lower MS related symptom

flare-ups• Score can be provided to clinician in advance of visit• Clinician reimbursed for telemedicine visit

BeCareLink MS Platform

Multiple Sclerosis Market Size• More Than 1M People In US

• Cost of MS Drugs per year is $63K to $104K annually

• Total Lifetime Costs is $4.1m Per Person With MS

Source: https://www.healthline.com/health/multiple-sclerosis/facts-statistics-infographic#12

Source: https://www.managedcaremag.com/archives/2018/10/ms-drugs-expensive-often-lifelong-and-not-cost-effective

$16.3 B TAM

$13M TM

$2.6 B SAM

TOTAL ADDRESSABLE MARKETMarket Size of MS Drugs in US

SERVED AVAILABLE MARKETAddressable Market of MS Drugs in US that can be impacted – 15% Market Share

TARGET MARKETMS Drugs in the US that can be impacted by BeCareLink

Current and Future Randomized Clinical Trials

Validate App Compared to MS Gold Standard

Validate App Compared to Falls Risk Gold Standard

Predict MS Disease Progression

Revenue Model• Payor Based – Fee For Value – PMPM Plus Success Fees• Pharma Based – Companion Digital Therapeutic Application to MS Drug

$0

$2,000,000

$4,000,000

$6,000,000

$8,000,000

$10,000,000

$12,000,000

2019 2020 2021 2022 2023 2024

BeCareLink Revenue Model

Total Revenue Total EBITDA

Awards and Accolades

Our Team

Tim Vartanian, MD, PhDClinical Advisor & Co-founderLeading Authority On Neural Regeneration And MS

Lawrence Rubin, PhDInventor & Co-founderExpert In AI, Machine Learning &Neural Networks In Healthcare

David Putrino, PhDComputational Neuroscience & Co-founderExpert In Neural & Motor Control And Brain Machine Interface

Alan Gilbert, MPA, FHIMSSChief Executive OfficerHealthcare Growth On Improved Outcomes And Reduced Costs

Michael Halem Chief Data SpecialistExpert In AI, Machine Learning & Neural Networks

Pierantonio Russo, MDClinical AdvisorExpert In Managed Care, Hospital At Home, And Reimbursement

Future Team (Post Financing)CFO, CTO, CSO, Project Manager

Future Focus• MS Pilots with multiple US based Centers of Excellence

• Replication of Gold Standard Test in Falls Risk – Berg Balance Scale

• After establishing traction in MS, focus on app for Parkinson’s, Stroke, Dementia, Alzheimer’s

• FDA Certification for Medical Device

www.HIMSSConference.org #HITventure

Alan Gilbert, MPA, FHIMSSBeCareLink@BeCareLink1